Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …

Simple Summary Due to its graft-versus-myeloma effect, allogeneic hematopoietic stem cell
transplantation (allo-SCT) can enable long-term survival or even cure in carefully selected …

Background Despite recent advances, multiple myeloma (MM) remains incurable. However,
the appearance of allogeneic stem cell transplantation (allo-SCT) through graft-versus …

Novel drugs have improved survival for patients with multiple myeloma in recent years.
However, the disease is still fatal. Allogeneic stem cell transplantation (Allo) has proven to …

The FDA approval of two monoclonal antibodies in 2015 has heralded a new era of targeted
immunotherapies for multiple myeloma (MM). In this review we discuss the recent …

The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple
myeloma is controversial. We analyzed the results of 205 patients transplanted in one center …

Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless
chosen with increasing frequency for patients suffering from multiple myeloma in Europe. To …

Objective To provide an overview of the hematopoietic stem cell transplantation (HSCT)
process specific to patients with multiple myeloma (MM) and their caregivers. Data Sources …

Methods We aimed to provide a comprehensive analysis in the recent 10 years to verify the
efficacy and survival outcome of alloHCT in MM patients. A total of 61 studies which provide …